Honolulu, HI – Quincy Bioscience, a research-based biotechnology company, is attending the annual Alzheimer’s Association International Conference on Alzheimer’s Disease (ICAD) sharing promising interim data from the Madison Memory Study, a randomized controlled trial, which shows the jellyfish protein apoaequorin improves cognitive function in individuals with memory concerns.
Box jellyfish are not a welcomed sight on Hawaii’s pristine beaches but there is another species of jellyfish invading the island of Oahu whose visit is welcomed. Aequorea victoria is the jellyfish from which the calcium-binding protein apoaequorin, a potential therapeutic for Alzheimer’s disease, is derived.
Quincy Bioscience representatives are attending the annual Alzheimer’s Association International Conference shared promising interim data which demonstrates the jellyfish protein improved cognitive testing scores by 14% in sixty days compared to placebo in the randomized controlled “Madison Memory Study,” which enrolled adults who had a memory concern. The average age in the study cohort of thirty-five individuals was 61 years old.
“We are looking forward to sharing the apoaequorin memory data with representatives and presenters at this year’s Alzheimer’s Association ICAD,” said Mark Underwood, president of Quincy Bioscience. “I am encouraged by all of the new research and hopeful pipelines presented at this year’s ICAD,” said Underwood, “but more excited that apoaequorin is in a deliverable form and available for people now that have memory concerns.”
